menu

T-cell Receptor (TCR) Sequencing Assay

TCR sequencing assay designed to interrogate V(D)J rearrangements in TCRβ and TCRy chains using RNA or total nucleic acids from whole blood or peripheral blood mononuclear cells (PBMC)

Our T- cell receptor sequencing assay targets and amplifies the TCR complementarity-determining region 3 (CDR3) and incorporates unique molecular indices to facilitate error correction and accurate counting of TCR clonotypes and their abundance and diversity at the mRNA level, using next generation sequencing on Illumina platforms. The TCR sequencing assay is part of our comprehensive immuno-oncology assay portfolio and is available for RUO or GCP applications.


Highlights:
  • Detects TCRβ and TCRy clonotypes that are actually expressed at the mRNA level
  • Molecular barcodes for error correction enable high accuracy and quantitative precision for tracking the dynamics of the T-cell repertoire over time

Assay format varies by application
Assay Format Sample Type RNA Input Requirements Applications
Standard Whole blood PBMC 400 ng Examine T-cell repertoire clonality and dominant TCR clonotypes
High Sensitivity Whole blood PBMC 1200 ng Examine rare TCR clonotypes

Assay specifications
Gene Targets T-cell receptor β/y chains, CDR3 region
Specimen Requirements Whole blood (4 mL), PBMC or cells (5 mln), purified RNA or total nucleic acids (1 µg)
Assay Method Immunoverse™ TCR targeted RNA sequencing
Platform Compatibility NextSeq 500, MiSeq
Regulatory Tier RUO, GCP
Deliverables Sample QC summary reports, TCRβ and TCRy sequences detected (nucleic acid and amino acid sequences, frequency and abundance, V segment utilization), and sample diversity
Microsatellite Instability Assay for Response to Immunotherapy

MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens

Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy

Gene expression and analysis for detection of 15 Immune Landscape Signatures

Read More